MPN-SG BiO | RS | Registerstudie zur Erfassung des biologischen Erkrankungsprofils und des klinischen Verlaufs bei Patienten mit BCR-ABL1 negativen myeloischen Neoplasien: Das MPNSG Biology and Outcome (BiO)-Projekt |
TL-895-201 |
Phase II |
A Phase 2 Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis |
XPORT-MF-034 |
Phase III |
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Eudract Nr. 2020-003883-19 |
XPORT-MF-044 |
Phase III |
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia |
POESIS |
Phase III |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Following a Suboptimal Response to Ruxolitinib |